EUCTR2016-000293-37-FR进行中（未招募）1 期
An open-label, multi-center rollover protocol for patientswho have participated in a Novartis-sponsored ribociclib(LEE011) study and are continuing to benefit fromribociclib as single agent or in combination with otherinvestigational treatments
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patient is currently enrolled in an eligible Novartis-sponsored ribociclib (LEE011) study and is receiving ribociclib as single agent or in combination with other investigational treatments.
- •- Patient is currently deriving clinical benefit from the study treatment, as determined by the investigator.
- •- Patient has demonstrated compliance, as assessed by the investigator, with the parent protocol requirements.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 2
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 19
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 19
排除标准
- •- Patients who have permanently discontinued from ribociclib (LEE011) in the parent protocol for any reason.
- •- Patients who do not meet parent protocol criteria to continue study treatment.
研究者
相似试验
进行中（未招募）
1 期
Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatmentsDifferent types of advanced cancerMedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10028997Term: Neoplasm malignant Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2023-508841-42-00ovartis Pharma AG119
招募中
2 期
An open-label, multi-center rollover protocol for patients
who have participated in a Novartis-sponsored ribociclib
(LEE011) study and are continuing to benefit from
ribociclib as single agent or in combination with other
investigational treatments2024-511125-61-00Novartis Pharma AG1
招募中
1 期
An open-label, multi-center rollover protocol for patientswho have participated in a Novartis-sponsored ribociclib(LEE011) study and are continuing to benefit fromribociclib as single agent or in combination with otherinvestigational treatmentsCTIS2024-511125-61-00ovartis Pharma AG4
招募中
不适用
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatmentssolid cancer(s)malignancy10027655NL-OMON51829ovartis1
进行中（未招募）
1 期
A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body.Biliary atresiaMedDRA version: 20.0Level: LLTClassification code 10004653Term: Biliary atresiaSystem Organ Class: 100000004850MedDRA version: 20.1Level: LLTClassification code 10004654Term: Biliary atresia, congenitalSystem Organ Class: 100000004850EUCTR2014-004693-42-FIIntercept Pharmaceuticals, Inc.72